Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust
September 6, 2017 8:30 AM EDT
CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, will ring Nasdaqs Closing Bell today in recognition of World Duchenne Awareness Day (WDAD), which is officially recognized around the globe on September 7, 2017.Â
As a company dedicated to DMD, Sarepta stands with the Duchenne community to raise awareness of this disease. On behalf of the employees at Sarepta, we would also like to take this opportunity to thank... More
September 6, 2017 7:00 AM EDT
-- Study achieved statistical significance on all primary and secondary biological endpoints --
-- Results further validate the Companys exon-skipping platform for the treatment of DMD --
CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced muscle biopsy results from its 4053-101 study, a Phase 1/2 first-in-human study conducted in Europe to assess the safety, tolerability, pharmacokinetics, and efficacy of golodirsen in 25 boys with confirmed... More
